|
|
Next Article 
Blood, Vol. 91 No. 1 (January 1), 1998:
pp. 1-2
EDITORIAL
A New Year Greeting From a New Editor
By
Kenneth Kaushansky MD
Seattle, WA
IT IS WITH great pleasure and sense of responsibility
that I write today as the eighth Editor of BLOOD. The position
of Editor-in-Chief of our Journal has traditionally been filled by a
well-established investigator in Hematology, who had convincingly
demonstrated both scientific expertise and editorial excellence during
many years of contribution. In both respects, I consider myself junior.
So it is with an untested belief that the Publications and Executive
Committees of the Society have given me their confidence; I promise to
do my best not only to maintain the scientific excellence of the
Journal, but to continue the work of my insightful predecessors in
improving BLOOD as it enters its sixth decade.
By all accounts BLOOD has grown to become an extremely
successful scientific enterprise. The readership of the Journal stands
at over 14,000, far exceeding our Society's growing membership. I
believe this reflects the scientific standing of BLOOD, an
opinion borne out by statistics. Last year, the Journal ranked highly
in every measure of scientific publications, having recently passed
CIRCULATION as the journal with the highest impact factor rate
of all medical subspecialty journals. Jim Griffin and the Associate
Editors deserve much credit for this standing, and our new Editorial
team and I hope to continue to improve upon this record.
Given this history of excellence, our new Editorial team plans to take
an "if it isn't broke, don't fix it policy." However, that is
not to say we plan on continuing without change. I believe there are
areas in which the Journal can benefit from midcourse corrections. Over
the next several months you will see changes that I hope reflect the
needs of both biomedical scientists and practicing hematologists. Our
Reviews are, on occasion, dense and difficult to digest. We hope to
trim these, providing concise review papers on scientific and clinical
topics of importance to our readership, each containing up-to-date
information designed to educate and stimulate both the uninitiated and
expert in the field. Many of these reviews will explore
cross-disciplinary topics in basic sciences, including apoptosis,
intercellular adhesion and communication, inside-out signaling, and the
cell cycle, subjects that are becoming increasingly important to
Hematologists and Oncologists. A portion of these reviews will assume a
new format, "Controversies in Hematology," a forum of data-based
point and counterpoint discussions by two leaders in a field who hold
opposite views. "Controversies in Hematology" will be designed to
objectively discuss both sides of an unresolved issue in Hematology,
provoke further discussion, and leave the reader to draw his or her own
conclusions. Examples of topics to be covered include the deterministic
versus permissive role of growth factors in hematopoiesis, the optimal
treatment for stage IIb Hodgkin's disease, whether to prophylactically
treat or observe an individual with Factor VLeiden, whether
to treat or observe PCR-determined minimal residual disease, and
whether to treat patients with acute nonlymphocytic leukemia with
chemotherapy alone or by transplant. We also plan to make more use of
the Editorial, both to convey matters of Journal policy and academic
concern, and to highlight papers of particular importance appearing in
each issue of BLOOD. This latter aspect will take the form of a
"News and Views" segment, much the way NATURE provides
commentary. Authored by members of the Editorial Board, this new forum
will be designed to draw attention to papers the Editors believe are of
widespread importance or represent a major paradigm shift. Overall, our
goals will be to maintain BLOOD as the premier Hematology
journal, to provide a forum for the presentation of outstanding
science, and to furnish the clinician with both the primary data needed
to guide patient care and to illuminate the scientific basis of future
therapies.
How will all of this be accomplished? Ironically, one of major issues
confronting our Journal is its tremendous success. At the time this
editorial appears, BLOOD will have received more than 2,600
manuscripts for consideration in 1997. As simple examination of the
thickness of each issue demonstrates, the growing size of the journal
reflects an attempt to keep up with an ever-increasing desire of
physicians and scientists to publish within our pages. In 1996 we
published over 11,000 pages, nearly a 70% increase since 1992.
However, as publishing costs rise, and the physical arm strength of our
members remains constant, it is becoming clear that we can no longer
maintain the philosophy of "publishing all the hematologic news
that's fit to print." We must limit our pages to the very best that
Hematology has to offer. This places increased importance on the
peer-review process; we will soon expand our Editorial Board, with the
goal of having every paper reviewed by at least one member of that
devoted body. This will require a greater commitment on behalf of our
Editorial Board members, but should provide a more balanced and
consistent approach to the difficult decisions of acceptance and
rejection.
Despite our general approach of not repairing what is working well, I
would like to take this opportunity to emphatically reinforce one
important issue, that of the sharing of reagents described in the pages
of our Journal. Although always an unstated principle of BLOOD,
making the renewable reagents described in scientific articles
available to qualified investigators in the field is now a stated
requirement of publication. The basis for this policy is
straightforward: the scientific process requires that a new finding, to
be established, must be reproducible. If a new finding is based on a
new reagent, it cannot be reproduced if that reagent is not available
to the scientific community for testing. The policy is simple and
applies to individual academic laboratories and to corporate
contributors alike. If you report on a new cDNA, monoclonal antibody,
cell line, or other easily renewable resource, you must make it
available to other qualified individuals with minimal restrictions if
you expect to continue to publish in BLOOD.
In closing I would like to thank Jim Griffin, for his counsel and
support, and the outgoing Associate Editors and members of the
Editorial Board for their tremendous service over the past 5 (or more)
years. You may think your term is over, but you will not be forgotten.
There are many more papers waiting for review! I thank in advance our
continuing Associate Editors and our new Associate Editors, Cynthia
Dunbar, Tomas Ganz, Jerome Groopman, and Dan Longo, and our entire 1998
Editorial Board, for their commitment and efforts. And I thank the
Publications and Executive Committees for providing me the opportunity
to contribute to an exciting scientific endeavor. I look forward to the
next 5 years with great anticipation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. G. Gobbi, C. Broglia, A. Levis, A. La Sala, F. Valentino, T. Chisesi, S. Sacchi, F. Corbella, L. Cavanna, E. Iannitto, et al.
MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors
Clin. Cancer Res.,
January 15, 2006;
12(2):
529 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schmitt, L. Gouya, E. Malonova, J. Lamoril, J.-M. Camadro, M. Flamme, C. Rose, S. Lyoumi, V. Da Silva, C. Boileau, et al.
Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria
Hum. Mol. Genet.,
October 15, 2005;
14(20):
3089 - 3098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jacquot, L. Macon-Lemaitre, E. Paris, T. Kobata, Y. Tanaka, C. Morimoto, S. F. Schlossman, and F. Tron
B cell co-receptors regulating T cell-dependent antibody production in common variable immunodeficiency: CD27 pathway defects identify subsets of severely immuno-compromised patients
Int. Immunol.,
July 1, 2001;
13(7):
871 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. E. Woodhead, T. J. Stonehouse, M. H. Binks, K. Speidel, D. A. Fox, A. Gaya, D. Hardie, A. J. Henniker, V. Horejsi, K. Sagawa, et al.
Novel molecular mechanisms of dendritic cell-induced T cell activation
Int. Immunol.,
July 1, 2000;
12(7):
1051 - 1061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jomaa, J. Wiesner, S. Sanderbrand, B. Altincicek, C. Weidemeyer, M. Hintz, I. Türbachova, M. Eberl, J. Zeidler, H. K. Lichtenthaler, et al.
Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs
Science,
September 3, 1999;
285(5433):
1573 - 1576.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. S. Haneline, T. A. Gobbett, R. Ramani, M. Carreau, M. Buchwald, M. C. Yoder, and D. W. Clapp
Loss of FancC Function Results in Decreased Hematopoietic Stem Cell Repopulating Ability
Blood,
July 1, 1999;
94(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bacsi, R. De Palma, G.P. Visentin, J. Gorski, and R.H. Aster
Complexes of Heparin and Platelet Factor 4 Specifically Stimulate T Cells From Patients With Heparin-Induced Thrombocytopenia/Thrombosis
Blood,
July 1, 1999;
94(1):
208 - 215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Liu, T. Sasaki, I. Kozieradzki, A. Wakeham, A. Itie, D. J. Dumont, and J. M. Penninger
SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival
Genes & Dev.,
April 1, 1999;
13(7):
786 - 791.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Bullrich, D. Rasio, S. Kitada, P. Starostik, T. Kipps, M. Keating, M. Albitar, J. C. Reed, and C. M. Croce
ATM Mutations in B-Cell Chronic Lymphocytic Leukemia
Cancer Res.,
January 1, 1999;
59(1):
24 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Haque, P. Harbor, M. Tabrizi, T. Yi, and B. R. G. Williams
Protein-tyrosine Phosphatase Shp-1 Is a Negative Regulator of IL-4- and IL-13-dependent Signal Transduction
J. Biol. Chem.,
December 18, 1998;
273(51):
33893 - 33896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hale, M.-J. Zhang, D. Bunjes, H. G. Prentice, D. Spence, M. M. Horowitz, A. J. Barrett, and H. Waldmann
Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection
Blood,
December 15, 1998;
92(12):
4581 - 4590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Tz. Hinkovska-Galcheva, L. A. Boxer, P. J. Mansfield, D. Harsh, A. Blackwood, and J. A. Shayman
The Formation of Ceramide-1-phosphate during Neutrophil Phagocytosis and Its Role in Liposome Fusion
J. Biol. Chem.,
December 11, 1998;
273(50):
33203 - 33209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. van Hennik, M. M.A. Verstegen, M. F.A. Bierhuizen, A. Limon, A. W. Wognum, J. A. Cancelas, J. Barquinero, R. E. Ploemacher, and G. Wagemaker
Highly Efficient Transduction of the Green Fluorescent Protein Gene in Human Umbilical Cord Blood Stem Cells Capable of Cobblestone Formation in Long-Term Cultures and Multilineage Engraftment of Immunodeficient Mice
Blood,
December 1, 1998;
92(11):
4013 - 4022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Liu, A. J. Oliveira-Dos-Santos, S. Mariathasan, D. Bouchard, J. Jones, R. Sarao, I. Kozieradzki, P. S. Ohashi, J. M. Penninger, and D. J. Dumont
The Inositol Polyphosphate 5-Phosphatase Ship Is a Crucial Negative Regulator of B Cell Antigen Receptor Signaling
J. Exp. Med.,
October 5, 1998;
188(7):
1333 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Homeister, M. Zhang, P. S. Frenette, R. O. Hynes, D. D. Wagner, J. B. Lowe, and R. M. Marks
Overlapping Functions of E- and P-Selectin in Neutrophil Recruitment During Acute Inflammation
Blood,
October 1, 1998;
92(7):
2345 - 2352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E Parker
Modulation of ATP-gated non-selective cation channel (P2X1 receptor) activation and desensitization by the actin cytoskeleton
J. Physiol.,
July 1, 1998;
510(1):
19 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
